Migraine has a unique, significant quality of life burden.

This analysis evaluates the progression of Alzheimer disease (AD) severity and compares the life expectancy and nursing home placement rates for AD patients with the same measures in the general population. Data from the Consortium to Establish a Registry for Alzheimer Disease were analyzed to estimate expected survival, time spent in each Clinical Dementia Rating stage, and nursing home admission rate for a hypothetical cohort of patients aged 70 years with new-onset AD. Corresponding estimates for the US general population were calculated from the 2004 National Nursing Home Survey and the 2003 life table estimates from the US Census Bureau. Deaths from all causes by age 80 years are expected in 61% of AD patients and in 30% of the general population. From the age of 70 to 80 years, a typical AD patient spends 4 years at Clinical Dementia Rating stage 3 (severe), 3 years at stage 2 (moderate), and 3 years at stage 1 (mild). Nursing home admission by the age of 80 years is expected for approximately 75% of surviving AD patients, but for only 4% of the general population. Among persons aged > or =65 years, reported age-adjusted and sex-adjusted mortality rates for AD increased to 33% from 1999 to 2004.

Given the strength, consistency, and predictable characteristics of the relationships, the algorithms appear to provide valuable and valid methods to estimate utilities from IBDQ scores (but not CDAI) in trials of Crohn's disease patients that have collected IBDQ scores but not utilities.

No abstract

No abstract